This is the authors' abstract. We don't add key points for this paper.
Gliomas are aggressive brain tumors that account for about one-third of all primary brain neoplasms, with an estimated global incidence of 3–6 cases per 100,000 annually and a poor prognosis. Standard treatment typically involves surgery, chemotherapy, and radiotherapy, which is particularly crucial for high-grade gliomas. Gliomas are highly heterogeneous and respond variably to radiation. Key elements influencing glioma radiosensitivity include age, clinical characteristics, histological and cellular markers, and surface receptors. Thus, identifying biomarkers related to radiosensitivity remains crucial to estimate treatment outcomes. Numerous studies have assessed molecular markers associated with radiosensitivity. However, it is also important to consider non-molecular factors, which have received significantly less attention thus far. This narrative review aims to comprehensively review different non-molecular biomarkers associated with radiosensitivity.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bordbar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: